Share this article
Share this article
LOS ANGELES, March 9, 2021 /PRNewswire/ CEO of Biostrap, a digital health company, goes public with his personal data showing the decline of his health after contracting SARS-CoV-2 and becoming symptomatic with COVID-19. Sameer Sontakey, 35, was first alarmed by his Biostrap app.
Vital biometrics that the wrist-worn wearable measures reported a significant deviation from Sontakey s healthy baseline.
(PRNewsfoto/Biostrap) It was Biostrap s early warning notification that prompted me to schedule a nasal swab test, which confirmed the positive diagnosis of SARS-CoV-2, Sameer Sontakey, Biostrap CEO, said.
Although most patients with COVID-19 present with mild symptoms, they still show significant biometric changes, including resting heart rate, heart rate variability, oxygen saturation, respiratory rate and arterial properties.
2021 Florida Animal Friend Grant Application Deadline Approaches
News provided by
Share this article
TAMPA, Fla., March 9, 2021 /PRNewswire/
Florida Animal Friend, an organization dedicated to saving the lives of unwanted cats and dogs throughout Florida, will soon close their grant application window for 2021. The grant application is
available online, but applications received after 8 p.m. on April 1 will not be accepted. Grants are awarded to organizations around the state that strive to improve the pet overpopulation problem by providing free or low-cost spay and neuter programs.
Grant applications received by the April 1 deadline will be reviewed by Florida Animal Friend s Grant Review Committee and scored for strengths in the following areas: target of important animal populations, ability to increase surgery numbers above the existing baseline, cost-benefit ratio, track record of the applicant and the applicant s sustainability. Once applicants make it past the Gran
Share this article
Share this article
ResearchAndMarkets.com s offering.
Global Anti-Adhesion Products Market to Reach $902.1 Million by 2027
Amid the COVID-19 crisis, the global market for Anti-Adhesion Products estimated at US$598.6 Million in the year 2020, is projected to reach a revised size of US$902.1 Million by 2027, growing at a CAGR of 6% over the period 2020-2027.
Synthetic, one of the segments analyzed in the report, is projected to record 6.7% CAGR and reach US$513.9 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Natural segment is readjusted to a revised 5.2% CAGR for the next 7-year period.
DarioHealth Reports Fourth Quarter and Full Year 2020 Results and Operational Highlights
USA - English
Successfully secured multiple accounts in the B2B channel which are already enrolling members and generating revenue
Upright acquisition expands digital therapeutics offering to include musculoskeletal, attracting interest from existing and prospective B2B2C customers
Completed financing with elite healthcare funds provides capital to execute on growth initiatives with cash and cash equivalents of approximately $90 million at closing of the financing
Company to host conference call and webcast 8:30 am ET today.
News provided by
Share this article
Share this article
NEW YORK, March 9, 2021 /PRNewswire/ DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the fourth quarter and full year 2020 and provided a corporate and commercial update.
Curaleaf Reports Record Fourth Quarter and Fiscal Year End 2020 Financial and Operational Results
Record Fiscal Year and Fourth Quarter 2020 Pro Forma Revenue(1)(2) of $767.1 Million and $238.8 Million, Respectively
Record Fiscal Year and Fourth Quarter 2020 Managed Revenue(1) of $653.0 Million, up 161% from 2019 and $233.3 Million, up 186% from 2019, Respectively
Record Fiscal Year and Fourth Quarter 2020 Adjusted EBITDA(1) of $144.1 Million up 456% from 2019 and $53.8 Million up 289% from 2019, Respectively, as Operations Across 23 States Continue to Scale
Raised $289.8 Million of Net Proceeds from a Common Stock Offering and Debt Offering in January 2021, Providing the Company with Capital to Pursue Additional Organic and Inorganic Growth Opportunities
News provided by
Share this article